Royan Institute is a renowned center committed to multidisciplinary, campus-wide, integration and collaboration of academic and medical personnel for understanding male/ female infertility, embryo development, stem cell biology, and biotechnology. Royan Institute provides comprehensive services for the infertility treatment, regenerative medicine/cell therapy, production of recombinant proteins and development of biological products.
Knowledge-based product WhartoCell, developed on the basis of umbilical cord–derived stem cells and indigenous technology, has received authorization from the Food and Drug Administration for the treatment of osteoarthritis, with the aim of reducing inflammation and promoting cartilage regeneration.
A specialized meeting on the commercialization agenda of Royan Institute for the new year was convened with the participation of the institute’s senior executives and representatives of CellTech Pharmed.
